Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 9/20 | 0.58 |
| ▸ | ST14 | Q9Y5Y6 | 4/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.58 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.58 |
| ▸ | F10 | P00742 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12085588 | 1.00 | PRSS1 (0.58) | PRSS1ST14PRSS2PRSS3F2 | |
| SCHEMBL12085592 | 0.98 | PRSS1 (0.56) | PRSS1ST14PRSS2PRSS3F2 | |
| SCHEMBL14448135 | 0.92 | PRSS1 (0.50) | PRSS1ST14PRSS2PRSS3F2 | |
| SCHEMBL23468483 | 0.92 | PRSS1 (0.50) | PRSS1ST14PRSS2PRSS3F2 | |
| SCHEMBL14397030 | 0.88 | PRSS1 (0.46) | PRSS1ST14PRSS2PRSS3F2 | |
| SCHEMBL23468519 | 0.87 | PRSS1 (0.46) | PRSS1ST14PRSS2PRSS3F2 | |
| SCHEMBL13714812 | 0.79 | PRSS1 (0.53) | PRSS1ST14PRSS2PRSS3F2 | |
| SCHEMBL16808247 | 0.77 | ITGB3 (0.52) | PRSS1ST14PRSS2PRSS3F2 | |
| SCHEMBL7428912 | 0.76 | PRSS1 (0.50) | PRSS1ST14PRSS2PRSS3F2 | |
| SCHEMBL1445939 | 0.75 | PRSS1 (0.48) | PRSS1ST14PRSS2PRSS3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| WO-2014110154-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-7312244-B2 | Polyamine analog-amino acid conjugates useful as anticancer agents | CELLGATE, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | CELLGATE, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | CELLGATE, INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2007040535-A1 | USE OF POLYAMINE ANALOGS FOR TREATMENT AND PREVENTION OF INTESTINAL POLYPS | CELLGATE, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-7186825-B2 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186825-B2 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232677-A1 | Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds | SRM, SMS, PCNA | PRSS1 1076/4885ST14 728/4885PRSS2 4035/4885 |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | SRM, PYCR1, PAICS | PRSS1 1163/4885ST14 2100/4885PRSS2 2494/4885 |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | SRM, PMP22, SMS | PRSS1 2171/4885ST14 4477/4885PRSS2 3358/4885 |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | PRSS1 1484/4885ST14 2891/4885PRSS2 3486/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | PRSS1 1484/4885ST14 2891/4885PRSS2 3486/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | PRSS1 3411/4885ST14 3465/4885PRSS2 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.